Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Roivant, a biopharmaceutical firm, reported its financial results and progress on clinical programs for the first quarter of the fiscal year 2024 during an earnings call led by CEO Matthew Gline.</li><li>This quarter, Roivant emphasized its ongoing efforts in expanding and executing its clinical pipeline, highlighting several key updates and future expectations.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Roivant, a biopharmaceutical firm, reported its financial results and progress on clinical programs for the first quarter of the fiscal year 2024 during an earnings call led by CEO Matthew Gline.This quarter, Roivant emphasized its ongoing efforts in expanding and executing its clinical pipeline, highlighting several key updates and future expectations.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Roivant Sciences Ltd.: Expansion of VTAMA Applications & Clinical Pipeline Developments Driving Our Bullishness! - Major Drivers

<ul><li>Roivant's latest financial and business developments indicate both potential and challenges.</li><li>The company reported a series of product updates and financial adjustments aimed at fostering growth and efficiency.</li><li>Notably, Roivant's executive team highlighted fiscal responsibility through renegotiations of Dermavant's obligations, which are projected to reduce costs significantly.</li></ul>

Roivant's latest financial and business developments indicate both potential and challenges.The company reported a series of product updates and financial adjustments aimed at fostering growth and efficiency.Notably, Roivant's executive team highlighted fiscal responsibility through renegotiations of Dermavant's obligations, which are projected to reduce costs significantly.

Roivant Sciences Ltd.: Focus on Immunological Innovations Through Immunovant & Other Pipeline Expansion! - Major Drivers

<ul><li>This is our first report on Roivant.</li><li>The company's Q3 2023 earnings were decent and the neutral positives can be highlighted from the continuous growth of VTAMA, ROIV's best-selling branded topical in psoriasis, recording over 300,000 prescriptions and revenues of $20.7 million.</li><li>Additionally, the pipeline for Roivant has compelling developments, with brepocitinib showing promising potential in orphan rheumatology.</li></ul>

This is our first report on Roivant.The company's Q3 2023 earnings were decent and the neutral positives can be highlighted from the continuous growth of VTAMA, ROIV's best-selling branded topical in psoriasis, recording over 300,000 prescriptions and revenues of $20.7 million.Additionally, the pipeline for Roivant has compelling developments, with brepocitinib showing promising potential in orphan rheumatology.

Roivant Sciences Ltd.: Initiation Of Coverage - Acquisition Of New Programs To Diversify In Biosciences! - Major Drivers

External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Key points (machine generated)<ul><li>Roivant Sciences is set to close a $7.25 billion deal with Roche for Telavant, bringing their total value to $12 billion.</li><li>Despite the negative sentiment in the biotech industry, ROIV shares have the potential for over 100% upside with minimal downside, making it an attractive investment opportunity.</li><li>ROIV is likely to return capital to shareholders, benefiting existing holders such as Softbank and Sumitomo.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Roivant Sciences is set to close a $7.25 billion deal with Roche for Telavant, bringing their total value to $12 billion.Despite the negative sentiment in the biotech industry, ROIV shares have the potential for over 100% upside with minimal downside, making it an attractive investment opportunity.ROIV is likely to return capital to shareholders, benefiting existing holders such as Softbank and Sumitomo.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Roivant Sciences Ltd (ROIV) - Wednesday, Dec 13, 2023

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Our long-term outlook remains neutral on the S&amp;P 500 (SPX) as of our 8/6/24 Compass, after being bullish since early-November 2023.</li>
<li>Since late-July discussed expectations for a 1-to 4-month pullback/consolidation on SPX and QQQ; now it's likely to last closer to four months, and potentially 4- to 6-months from 7/17/24.</li>
<li>At that point the market will decide which way this consolidation resolves. Throughout this pullback we have said that this consolidation could end up being a significant topping pattern.</li>
</ul>


Our long-term outlook remains neutral on the S&amp;P 500 (SPX) as of our 8/6/24 Compass, after being bullish since early-November 2023.
Since late-July discussed expectations for a 1-to 4-month pullback/consolidation on SPX and QQQ; now it's likely to last closer to four months, and potentially 4- to 6-months from 7/17/24.
At that point the market will decide which way this consolidation resolves. Throughout this pullback we have said that this consolidation could end up being a significant topping pattern.


Upgrading Staples, Real Estate, and Health Care to Overweight; List of Concerns Continues to Grow

United States

Roivant Sciences Ltd. operates as a healthcare company. The Company offers investigational drugs in development for therapeutic areas such as dermatology, immunology, and respiratory diseases, as well as provides healthcare technologies which help healthcare institutions share and aggregate data. Roivant Sciences provides services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Roivant Sciences Ltd (ROIV US)

Roivant Sciences Ltd.: Expansion of VTAMA Applications & Clinical Pipeline Developments Driving Our Bullishness! - Major Drivers

Roivant, a biopharmaceutical firm, reported its financial results and progress on clinical programs for the first quarter of the fiscal year 2024...

Baptista Research

Roivant Sciences Ltd.: Focus on Immunological Innovations Through Immunovant & Other Pipeline Expansion! - Major Drivers

Roivant's latest financial and business developments indicate both potential and challenges. The company reported a series of product updates and...

Baptista Research

Roivant Sciences Ltd.: Initiation Of Coverage - Acquisition Of New Programs To Diversify In Biosciences! - Major Drivers

This is our first report on Roivant. The company's Q3 2023 earnings were decent and the neutral positives can be highlighted from the continuous...

Baptista Research

Roivant Sciences Ltd (ROIV) - Wednesday, Dec 13, 2023

Roivant Sciences is finalizing a deal with Roche for their company Telavant for $7.25 billion, which would bring their total value to $12, despite...

Value Investors Club

Upgrading Staples, Real Estate, and Health Care to Overweight; List of Concerns Continues to Grow

Upgrading Staples $XLP, Real Estate $XLRE, Health Care $XLV to Overweight; List of Concerns Continues to Grow; Dow $DJI, Equal-Weight S&P 500 $RSP,...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)